Trump expected to impose new tariffs on certain pharmaceutical drugs

100% tariff proposed on imports of patented drugs and active ingredients under a draft 'Most Favored Nation' order; companies can avoid levies by striking direct-to-consumer deals with the administration or reshoring production. Firms that relocate production could get a reduced 20% tariff for four years, reverting to 100% in 2030. Draft is not final and exemptions are unclear — this is a sector-moving regulatory risk that could materially pressure non-participating pharma names, incentivize reshoring, and risk higher consumer prices.

Analysis

The proposed 100% tariff functions as a scorched-earth bargaining chip: it makes immediate imported-patented-drug volumes economically untenable for many manufacturers and distributors unless they either cut deals with the administration or onshore production. That creates a two-track market in weeks–months — firms that can credibly negotiate carve-outs will see downside avoided, while import-heavy small/mid caps and API exporters face a binary margin shock if enforcement is broad.

Second-order winners are capacity providers and the US CDMO/API onshorers: capex to rebuild API and sterile-fill capacity is a multi-year story (12–36 months) and will support equipment, analytics, and service vendors, driving structural margin expansion once utilization climbs above 70–80%. Conversely, global distributors and PBM/distribution fee models face contracting revenue and operational disruption as commercial flows and pricing mechanics are renegotiated.

Timing and tail-risks are asymmetric: stock moves will come immediately on announcement and in the following 30–90 days as companies sign deals, but the durable industrial shift only materializes over 1–3 years and depends on capital intensity, FDA inspection timelines, and labor. Material reversal vectors include rapid litigation/WTO pushback, narrow regulatory drafting that exempts large swathes of drugs, or political backtracking ahead of an election — any of which could compress the repricing into a short-lived event.

Contrarian angle: the 100% number is deliberately maximalist and likely to be pared back — it’s an instrument to accelerate bilateral negotiations rather than a permanent tariff schedule. That means current dispersion in names is an opportunity: some distributors and broad biotech indices look over-penalized relative to the actual legal and implementation risk, creating defined-risk trades around near-term catalysts (deal announcements, agency rulemaking, court filings).

Key Decisions for Investors

• Long CTLT (Catalent) 12–24 month calls or buy-and-hold stock: exposure to onshoring/CDMO capacity; thesis wins if utilization rises above 70% within 18–36 months. Target upside 40–80% vs downside ~25% if policy stalls — use 12–18 month call spreads to cap cost.
• Long TMO (Thermo Fisher) 9–18 month calls (or 0.5–1% portfolio equity): benefits from lab / API equipment and pharma services demand during onshoring. Expect 20–40% upside on a sustained capex cycle; protect with 25% trailing stop or sell into strong headlines.
• Pair trade — short MCK (McKesson) or CAH (Cardinal Health) 3–9 month puts / outright short vs long CTLT: distributors are exposed to margin squeeze and flow disruption; target 20–30% downside if tariffs are enforced broadly within 90 days. Hedge via size (max 0.5% net portfolio risk) and close on regulatory clarification.
• Pair trade — long PFE or MRK (large-cap pharma) vs short IBB (biotech ETF) over 3–12 months: big pharm can negotiate carve-outs or onshore capex and will be less binary than small-cap, which is more API/import-dependent. Aim for asymmetric 2:1 reward:risk — trim positions on company-specific deal announcements or court rulings.